Advertisement
The announcement of Kosan's first quarter 2008 financial results will befollowed by a conference call and live webcast on May 1, 2008 at 1:30 p.m.Pacific / 4:30 p.m. Eastern. Interested parties may access the live call bydialing 888.680.0878 (US) or 617.213.4855 (international), access code63268386. To pre-register for the call, go tohttps://www.theconferencingservice.com/prereg/key.process?key=PLGLKCFUP orvisit the "Investors/Press" page at http://www.kosan.com.
Advertisement
Interested parties may listen to the webcast live at http://www.kosan.comby clicking on the "Webcasts" tab under the heading, "Investors/Press."
The webcast is also being distributed over Thomson's Investor DistributionNetwork to both institutional and individual investors. Individual investorscan listen to the call through Thomson's individual investor center athttp://www.earnings.com or by visiting any of the investor sites in Thomson'sIndividual Investor Network. Institutional investors can access the call viaThomson's password-protected event management site, StreetEvents, athttp://www.streetevents.com. A telephonic replay will be available throughMay 8, 2008 by dialing 888-286-8010, access code: 17626068. Internationalcallers can dial 617-801-6888, access code: 17626068.
About Kosan
Kosan Biosciences is a biotechnology company advancing two new classes ofanticancer agents through clinical development -- a Hsp90 (heat shockprotein 90) inhibitor and an epothilone. Hsp90 inhibitors have a novelmechanism of action targeting multiple pathways involved in cancer cell growthand survival. Tanespimycin (KOS-953) is being tested in combination withVelcade(R) (bortezomib) in patients with multiple myeloma in a clinicalprogram called TIME. Tanespimycin is also being studied in HER2-positivemetastatic breast cancer in combination with Herceptin(R) (trastuzumab).Epothilones inhibit cell division with a mechanism of action similar totaxanes, one of the most successful classes of anti-tumor agents. KOS-1584 isin a Phase 2 clinical trial in patients with non-small cell lung cancer.Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for developmentin gastroesophagel reflux disease, is in a Phase 1 trial. For additionalinformation on Kosan Biosciences, please visit the company's website athttp://www.kosan.com.
Velcade(R) (bortezomib) is a registered trademark of MillenniumPharmaceuticals, Inc.
Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.
SOURCE Kosan Biosciences Incorporated
